A Phase I, open-label study evaluating the pharmacokinetics and safety profile of tiragolumab combined with atezolizumab in Chinese patients with locally advanced or metastatic solid tumors
Latest Information Update: 25 Oct 2024
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary) ; Tiragolumab (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- 24 May 2023 New trial record
- 19 Apr 2023 Results (Data cutoff: Feb 10, 2022) presented at the 114th Annual Meeting of the American Association for Cancer Research.